Sanofi Partners with Shenzhen’s Pingshan District to Boost Innovative Vaccines in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has signed a partnership agreement with the Pingshan district...
NASDAQ: SNY
AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...
Sanofi’s Sarclisa Approved for Import in Shenzhen via Greater Bay Area Scheme
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater...
Sanofi’s VaxigripTetra Approved for Pediatric Influenza Vaccination in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical...
CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs
The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
Sanofi’s Q3 Sales Rise 9% on Dupixent and Flu Vaccine
French pharmaceutical major Sanofi (NASDAQ: SNY) released its Q3 2022 financial report, recording EUR 12.482...
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...
Sanofi’s Q2 Earnings Show 8.1% Global Sales Growth, Led by Dupixent and China Expansion
France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3...